Literature DB >> 16220112

Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics.

Oreste E Salavaggione1, Liewei Wang, Mathieu Wiepert, Vivien C Yee, Richard M Weinshilboum.   

Abstract

Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs. Genetic polymorphisms for TPMT are a major factor responsible for large individual variations in thiopurine toxicity and therapeutic effect. The present study investigated the functional effects of human TPMT variant alleles that alter the encoded amino acid sequence of the enzyme, TPMT*2, *3A, *3B, *3C and *5 to *13. After expression in COS-1 cells and correction for transfection efficiency, allozymes encoded by these alleles displayed levels of activity that varied from virtually undetectable (*3A,*3B and *5) to 98% (*7) of that observed for the wild-type allele. Although some allozymes had significant elevations in apparent Km values for 6-mercaptopurine and S-adenosyl-L-methionine (i.e. the two cosubstrates for the reaction), the level of enzyme protein was the major factor responsible for variation in activity. Quantitative Western blot analysis demonstrated that the level of enzyme protein correlated closely with level of activity for all allozymes except TPMT*5. Furthermore, protein levels correlated with rates of TPMT degradation. TPMT amino acid sequences were then determined for 16 non-human mammalian species and those sequences (plus seven reported previously, including two nonmammalian vertebrate species) were used to determine amino acid sequence conservation. Most human TPMT variant allozymes had alterations of residues that were highly conserved during vertebrate evolution. Finally, a human TPMT homology structural model was created on the basis of a Pseudomonas structure (the only TPMT structure solved to this time), and the model was used to infer the functional consequences of variant allozyme amino acid sequence alterations. These studies indicate that a common mechanism responsible for alterations in the activity of variant TPMT allozymes involves alteration in the level of enzyme protein due, at least in part, to accelerated degradation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220112     DOI: 10.1097/01.fpc.0000174788.69991.6b

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  42 in total

Review 1.  The pharmacogenetics research network: from SNP discovery to clinical drug response.

Authors:  K M Giacomini; C M Brett; R B Altman; N L Benowitz; M E Dolan; D A Flockhart; J A Johnson; D F Hayes; T Klein; R M Krauss; D L Kroetz; H L McLeod; A T Nguyen; M J Ratain; M V Relling; V Reus; D M Roden; C A Schaefer; A R Shuldiner; T Skaar; K Tantisira; R F Tyndale; L Wang; R M Weinshilboum; S T Weiss; I Zineh
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

2.  Glutathione s-transferase p1: gene sequence variation and functional genomic studies.

Authors:  Ann M Moyer; Oreste E Salavaggione; Tse-Yu Wu; Irene Moon; Bruce W Eckloff; Michelle A T Hildebrandt; Daniel J Schaid; Eric D Wieben; Richard M Weinshilboum
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

Review 3.  Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population.

Authors:  Wen-ying Shu; Jia-li Li; Xue-ding Wang; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

Review 4.  Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.

Authors:  R Tamm; R Mägi; R Tremmel; S Winter; E Mihailov; A Smid; A Möricke; K Klein; M Schrappe; M Stanulla; R Houlston; R Weinshilboum; Irena Mlinarič Raščan; A Metspalu; L Milani; M Schwab; E Schaeffeler
Journal:  Clin Pharmacol Ther       Date:  2017-02-01       Impact factor: 6.875

Review 5.  Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.

Authors:  Richard M Weinshilboum
Journal:  Cell Mol Neurobiol       Date:  2006-06-29       Impact factor: 5.046

6.  High-resolution melting analysis of the TPMT gene: a study in the Polish population.

Authors:  Marzena Skrzypczak-Zielinska; Pawel Borun; Katarzyna Milanowska; Ludwika Jakubowska-Burek; Oliwia Zakerska; Agnieszka Dobrowolska-Zachwieja; Andrzej Plawski; Ursula G Froster; Marlena Szalata; Ryszard Slomski
Journal:  Genet Test Mol Biomarkers       Date:  2012-12-19

7.  Genetic polymorphisms of NQO1, CYP1A1 and TPMT and susceptibility to acute lymphoblastic leukemia in a Tunisian population.

Authors:  Slah Ouerhani; Nouha Cherif; Ikbel Bahri; Ines Safra; Samia Menif; Salem Abbes
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

8.  Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation.

Authors:  Fang Li; Liewei Wang; Rebecca J Burgess; Richard M Weinshilboum
Journal:  Pharmacogenet Genomics       Date:  2008-12       Impact factor: 2.089

9.  Molecular dynamics simulation of a human thiopurine S-methyltransferase complexed with 6-mercaptopurine model.

Authors:  Wanwimon Mokmak; Sissades Tongsima; Ekachai Jenwitheesuk
Journal:  Bioinformation       Date:  2009-09-05

10.  Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme.

Authors:  Qiping Feng; Suda Vannaprasaht; Yi Peng; Susothorn Angsuthum; Yingyos Avihingsanon; Vivien C Yee; Wichittra Tassaneeyakul; Richard M Weinshilboum
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.